Related Experiment Video

Updated: Jun 20, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Sachin Gupta1, Bassel F El-Rayes

  • 1Department of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USA.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Pancreatic cancer remains chemo-resistant, but tyrosine kinase inhibitors offer targeted therapies. While early trials show disappointment, future strategies focus on improved patient selection and study designs for better outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Pancreatic cancer exhibits significant chemo-resistance, with gemcitabine as the sole approved agent since 1996.
  • Tyrosine kinase inhibitors (TKIs) represent a novel class of targeted therapies for cancer, including pancreatic cancer.

Purpose of the Study:

  • To review the clinical development of TKIs in pancreatic cancer.
  • To discuss strategies for future TKI drug development in this disease.

Main Methods:

  • Review of current clinical trials and literature on tyrosine kinase inhibitors in pancreatic cancer.
  • Analysis of challenges in pancreatic cancer clinical trial design and patient selection.

Main Results:

  • Erlotinib, a prototype TKI, has shown efficacy and gained approval for advanced pancreatic cancer.
  • Other TKIs targeting VEGFR, PDGFR, and Src kinases have yielded disappointing preliminary results in clinical trials.

Conclusions:

  • Despite challenges, TKIs offer a more selective approach to pancreatic cancer treatment.
  • Future research must focus on improved patient stratification, combination therapies, and enhanced preclinical models for successful TKI development.
Keywords:
erlotinibpancreatic cancertyrosine kinase inhibitors

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...